GRANTS:

• Total >£32,000,000 from Wellcome Trust, EU, US National Institutes of Health (NIAID), MRC, Fungal Infection Trust, National Institute for Health Research, Moulton Trust, Carigest and other charities.

IMPACTS:

• Led the RCT comparing voriconazole and amphotericin B leading to worldwide licensure of voriconazole for invasive aspergillosis (NEJM, 2002), achieved $800M in worldwide sales.
• Founded F2G Ltd which has a novel oral and intravenous antifungal agent (with a novel mode of action) in phase 2, and now funded for completion of phase 3 studies and filing for regulatory approval.
• Developed and lead multiple online education initiatives: The Aspergillus Website www.Aspergillus.org.uk, LIFE Worldwide www.fungaleducation.org and a microscopy and histopathology training course in multiple languages www.microfungi.net.
• Led the A. fumigatus genome sequencing project (since 1999), the coordinated analysis of the A. fumigatus, A. nidulans and A. oryzae genomes (since 2003), which lead to a triplet of papers published in Nature in 2005. Over 100 additional genomes are now being sequenced, >50% from Manchester.
• Founder Director of the National Aspergillosis Centre, the world’s first national clinical centre for any fungal disease, based on clinical descriptions and renaming of chronic pulmonary aspergillosis and documenting response to antifungal therapy, 2009-2020
• Made the first global estimates of chronic and allergic aspergillosis (2011-2013), aspergillosis in cystic fibrosis and national estimates of serious fungal diseases in >100 countries, 80 published or in press.
• Co-authored and/or lead Clinical Guidelines – diagnostics for fungal diseases (Lancet Infect Dis, 2015), invasive aspergillosis (IDSA in 2000, 2008, 2016, ESCMID 2018) and the world’s first for chronic pulmonary aspergillosis (Eur Resp J, 2016; for LMICs, 2018).
• Founded Global Action for Fungal Infection (2013) which has advocated for universal access for diagnostics and antifungal agents. Drafted multiple international reports on Global Roadmap for Fungal Diseases (GAFFI, 2015), Essential Diagnostics for LMICs (GAFFI, 2018), Integration of fungal diseases in Health Systems in Latin America (GAFFI 2020), Diagnostic access in Africa (including imaging) (GAFFI, 2022): www.GAFFI.org
• Enabled (with many others) acceptance of amphotericin B, flucytosine, itraconazole, voriconazole and topical natamycin to be approved as Essential medicines by the WHO (2013-2017).
• Enabled (with many others) acceptance of fungal culture, direct microscopy, cryptococcal antigen, histoplasma antigen Aspergillus antigen and antibody and Pneumocystis PCR to be accepted as Essential Diagnostics by the WHO (2018-2020)
• Estimated the incidence and prevalence of serous fungal diseases in >80 countries: https://gaffi.org/media/country-fungal-disease-burdens/
• Submitted three REF21 Impact statements for UoA1 (Transforming patient outcome of pulmonary aspergillosis with better and faster diagnosis and therapy), UoA2 (Successfully tackling serious fungal diseases to transform global population health) and UoA5 (Defining global antifungal azole resistance in Aspergillus – enhancing diagnostics and driving drug discovery).

RECENT CONTRIBUTIONS TO GUIDELINES AND CONFERENCES:

• BSAC Working party on Endocarditis, 2009-2011.
• Co-Chairman, Advances Against Aspergillosis, Istanbul, January 26-28th, 2012.
• Chairman, European Academy for Allergy and Clinical Immunology (EAACI) Task Force on Fungal
• Allergy in Asthma, 2012 -.
• Co-Chairman, Advances Against Aspergillosis 6, Madrid, February 27-March 1st, 2014.
• Member, ESCMID Invasive aspergillosis guidelines group 2013-2016
• Co-Chairman, Advances Against Aspergillosis 7, Manchester, March 3-5th, 2016.
• Member, IDSA Aspergillosis guidelines group, 2013-2016
• Member, InBev-BAILLET LATOUR (IBL) Fund (Laureate Prize Committee, Infectious Diseases), 2015 –
• Co-Chairman, Advances Against Aspergillosis 8, Lisbon, February 1-3rd, 2018.
• Co-Chairman, Advances Against Aspergillosis and Mucormycosis 9, Lugano, February 27-29, 2020.
• Co-Chairman, Advances Against Aspergillosis and Mucormycosis 10, Online, February 2-3, 2022.
• Co-Chairman, Advances Against Aspergillosis and Mucormycosis 11, Milan, January 27-29, 2024.

PUBLICATIONS:

• Over 750 papers published. Personal citation index >100,000. Google H-index 132. No 1 cited research author in Europe in Mycology and 5th in Microbiology (2012). Highly cited researcher, cross subject, 2019, 2020, 2021, 2022 (Clarivate ISI Web of Science). Numerous book chapters, two patents.